FDA describes 'objectionable conditions' at New York State Psychiatric Institute

preview_player
Показать описание
The facility’s institutional review board failed to report a 2021 incident and “serious and ongoing noncompliance” by a principal investigator, according to a letter released by the federal agency this week.

The Transmitter is an essential resource for the neuroscience community, dedicated to helping scientists at all career stages stay current and build connections. The publication aims to deliver useful information, insights and tools to build bridges across neuroscience and advance research. As part of that mission, The Transmitter offers a steady stream of up-to-date news and analysis of the field, written by journalists and scientists.

Follow The Transmitter:

#science #research #neuroscience
  1. The Transmitter
Рекомендации по теме
FDA describes 'objectionable 0:06:23

FDA describes 'objectionable conditions' at New York State Psychiatric Institute

How FDA Can 0:02:06

How FDA Can React to Your 483 Response

BIMO, REMS, and 1:10:40

BIMO, REMS, and PADE Inspection Readiness (3of3) Jun. 19, 2018

Postmarketing Drug Safety 0:59:01

Postmarketing Drug Safety Compliance: 2019 Inspection Findings

FDA Clinical Investigator 1:47:20

FDA Clinical Investigator Training Course (CITC) 2024 – Day Three – Session Two

What to Expect 1:01:06

What to Expect after an Inspection: 483s, Responses and Beyond

How harmful can 0:06:43

How harmful can ultra-processed foods be for us? - BBC News

How to Prepare 0:59:19

How to Prepare for an FDA Inspection

What Meta-analysis Can 0:16:28

What Meta-analysis Can Tell You about the Performance of Bioanalytical Methods - Bioanalysis 2020

FDA Food Inspection 1:22:53

FDA Food Inspection Preparedness: What to Expect When You're Inspected

Nitrosamine Impurities-Aug 2023 0:44:52

Nitrosamine Impurities-Aug 2023 NDSRIs Limit USFDA Guidance | Control of Nitrosamine Guidance Feb-21

Compliance Training for 0:19:02

Compliance Training for Small Tobacco Manufacturers, Domestic Establishment Inspections

FDA Rare Disease 7:32:56

FDA Rare Disease Day 2023: “Intersections with Rare Diseases – A patient focused event”

Research Coordinator Enrichment 1:07:10

Research Coordinator Enrichment Series - 2/22/24 Preparing for an FDA Inspection

Risk Evaluation and 0:32:42

Risk Evaluation and Mitigation Strategies (REMS) Inspections (2of3) - Jun. 19, 2018

5 Weird and 0:12:13

5 Weird and Gross Things the FDA Allows in Your Food

EAS Webinar - 0:50:19

EAS Webinar - Managing FDA Inspections

Good Clinical Practice 2:45:40

Good Clinical Practice & Pharmacovigilance Compliance Symposium Day Three – AM

Generic Drugs Forum 1:07:41

Generic Drugs Forum 2022 – Day 1, Session 3

How to Successfully 0:51:53

How to Successfully Respond to FDA 483s and Warning Letters

Risk Evaluation and 0:57:37

Risk Evaluation and Mitigation Strategies (REMS) Compliance Program

FDA’s Bioresearch Monitoring 0:41:38

FDA’s Bioresearch Monitoring Program - Foreign Inspections and Program Updates

Routine Surveillance Inspection 0:07:59

Routine Surveillance Inspection by FDA

Pre-Approval Inspections: What 0:41:31

Pre-Approval Inspections: What to Expect When Being Inspected (15of15) REdI – May 29-30, 2019